Loading...
In the randomized Women's Health Initiative (WHI) study, postmenopausal women treated with estrogen-progestin hormone therapy (HT) had higher incidence of breast cancer than did placebo recipients (JW Gen Med Jul 26 2002). An observational WHI study paralleled the randomized trial. In this report from the observational study, researchers present data on breast cancer incidence among 41,000 women who had negative mammograms within 2 years of study entry and who used either estrogen-progestin HT (16,000) or no HT (25,000).
During 11 years of follow-up, 2200 invasive breast cancers were diagnosed. With adjustments for numerous demographic and clinical variables, the annual incidence of breast cancer was significantly higher in the HT users than…